Ari VanderWalde is Director of Research at West Cancer Center and Research Institute in Memphis, Tennessee. An internationally recognized cancer researcher, Dr. VanderWalde holds a dual appointment with the University of Tennessee Health Science Center as Associate Vice Chancellor for Clinical Research and Associate Professor in Hematology/Oncology. His primary research is in melanoma, immunotherapy, and targeted therapies. In addition to the above duties, Dr. VanderWalde serves as the inaugural co-chair of the West Cancer Center Molecular Tumor Board, which has been in operation since 2014. In 2019, he was also appointed inaugural chair of the Virtual Molecular Tumor Board for Caris Life Sciences. He is the editor-in-chief of Elsevier’s PracticeUpdate Center of Excellence for Advanced Melanoma, and serves as the medical director for the Clinical Trials Network of Tennessee (CTN2) and senior medical director for George Clinical, an oncology based CRO.